Frank W. G. Leebeek MD, PhD

Frank Leebeek, MD, Ph.D. obtained his medical degree from the Erasmus University in Rotterdam, the Netherlands in 1990. He earned his Ph.D. degree in clinical studies on fibrinolysis inhibitors synthesized by the liver at the Erasmus University in Rotterdam. He subsequently worked as a post-doctoral fellow for two years at the University of North Carolina at Chapel Hill, USA to study the structure-function of the interleukin-6 and fibrinogen synthesis. He was trained as a hematologist at the Erasmus University Medical Center in Rotterdam, where he was appointed full professor in 2009. Since 2017 he is head of the department of Haematology.

He is coordinating a research team on Hemostasis and Thrombosis with several research topics. This includes inherited bleeding disorders, especially von Willebrand disease and Hemophilia, such as gene therapy studies in Hemophilia B. He is the principal investigator of the Willebrand in the Netherlands (WiN) study. In addition, he investigates the etiology and management of abdominal vein thrombosis and the role of coagulation in the pathogenesis of arterial thrombosis.

He has been secretary of the Dutch Society of Thrombosis and Haemostasis, chairman of the Dutch Hemophilia doctors organization, and is currently a board member of the Dutch Society of Haematology. He is co-chair of the SSC on the von Willebrand Factor of the ISTH. Dr. Leebeek has (co-)authored over 300 scientific publications listed in PubMed, 20 book chapters, and contributed to Dutch treatment guidelines on hemophilia and von Willebrand’s disease and venous thrombosis.